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SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in
solid tumours
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Summary SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound
in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase
I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells
at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and
are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour
cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by
fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal
tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the
cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its
intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy
and chemotherapy. Finally, the major unanswered questions on the drug are outlined.
Why develop a hypoxia-selective cytotoxic drug?
A key strategy in cancer treatment is to try to exploit some
intrinsic difference between normal and malignant tissues.
One such difference is that a large proportion of solid
tumours contain cells at lower levels of oxygenation than
occurs in normal tissues. Such hypoxia in tumours is found
in the vast majority of transplanted rodent tumours
(Moulder & Rockwell, 1987) and in human tumours xeno-
grafts in immunodeficient mice (Rockwell & Moulder, 1990).
There is also compelling evidence from a variety of techni-
ques that hypoxic cells are also present in human solid
tumours (Hockel et al., 1991; Mueller-Klieser et al., 1981;
Vaupel et al., 1991). However, the lower oxygenation level of
many solid tumours compared to normal tissues has only
recently been seen as therapeutically exploitable. Indeed, be-
cause of the resistance of hypoxic cells to killing by ionising
radiation, their presence in tumours would be expected to
adversely affect cure rates in radiotherapy, and there is con-
siderable evidence that this is the case for several types of
malignancies (Bush et al., 1978; Gatenby et al., 1988; Henk &
Smith, 1977; Overgaard et al., 1986). Preclinical studies sug-
gest that hypoxic cells may also be refractory to certain
chemotherapeutic drugs (Kennedy, 1987; Sartorelli, 1988;
Tannock & Guttman, 1981).
Three general strategies have been developed to overcome
the perceived problem of the hypoxic cells in solid tumours.
First, efforts have been made to increase tumour oxygenation
using a variety of means, the most recent of which is to
combine nicotinamide with carbogen (95% 02 plus 5% CO2)
(Chaplin et al., 1991; Kjellen et al., 1991). The second
approach has been to develop chemical sensitisers to pre-
ferentially increase the radiation sensitivity of the hypoxic
cells (Adams, 1981; Brown, 1989). A third approach has been
to develop hypoxic cell cytotoxins, agents that can selectively
kill hypoxic cells (Kennedy, 1987; Rockwell et al., 1982;
Sartorelli, 1988; Zeman et al., 1986).
For each of these three general approaches, the rationale is
to overcome the problem of hypoxic cells in tumours. How-
ever, it has recently been proposed that the presence of
hypoxic cells may be an advantage to the therapy of tumours
(Brown & Koong, 1991). This would only be the case, how-
ever, under certain conditions, namely:
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(1) An agent with high selective toxicity for hypoxic cells is
combined with one with selective toxicity to aerobic
cells (such as ionising radiation).
(2) The dynamics of the tumour are such that the percent
of hypoxic and aerobic cells in the tumour at the time
of each of the treatments with the combination of
agents is roughly the same as at the time of the first
treatment (i.e., that both reoxygenation and 'rehypoxia-
tion' (Brown & Lemmon, 1992) occur following each
treatment).
This is the rationale for developing an agent with high
selective toxicity for hypoxic cells. Although this biological
rationale was not appreciated at the time, the paradigm for a
bioreductive drug was suggested many years ago when Sar-
torelli and colleagues (Lin et al., 1972) proposed that the low
oxygen levels of solid tumours might be conducive to bio-
reductive metabolism of a drug to generate a compound
more toxic than the parent compound. This concept of bio-
reductive activation has been extensively reviewed (e.g. Ken-
nedy, 1987; Lin et al., 1976; Moore, 1977), and three general
classes of such agents are now known. First, the quinone
antibiotics of which mitomycin C is the prototype drug
(Rockwell et al., 1982; Sartorelli, 1988). Second, the nitro-
imidazoles, although developed as radiation sensitisers, show
preferential toxicity to hypoxic cells which is high in the case
of the dual function agent, RSU 1069 (Stratford & Stephens,
1989; Stratford et al., 1986). The third class of bioreductive
cytotoxic drugs are the benzotriazine di-N-oxides of which
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075,
tirapazamine) is the prototype compound (Zeman et al.,
1986). SR 4233 is presently in Phase 1 clinical testing and, in
fact, is the first drug to be introduced into the clinic purely as
a bioreductive cytotoxic agent. How best to exploit such an
agent and whether this, or other bioreductive drugs to fol-
low, can turn hypoxic cells into a therapeutic advantage in
solid tumours have yet to be answered.
Preferential cytotoxicity ofSR 4233for mammalian cells in
vitro
In the first report of the activity of SR4233, Zeman and
colleagues presented data on seven different cell lines of
hamster, mouse and human origin and found differential
hypoxic cytotoxicity for all the cell lines with a hypoxic
cytotoxicity ratio (concentration of drug in air divided by
concentration of drug in hypoxia to produce the same level
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of cell killing) of approximately 25 to 200 for the different
lines. Suggested by their data was the possibility that human
lines may have somewhat lower differential toxicities than
rodent lines. Figure 1 shows pooled data from several
experiments with three different cell lines showing a similar
broad range of hypoxic cytotoxicity ratios for these lines.
Values in the range of 50 to 200 have, in general, been
observed by most investigators (Adams et al., 1992; Costa et
al., 1989; Stratford & Stephens, 1989), although it has also
been reported that certain cell lines with repair deficiencies
have somewhat lower differential cytotoxicities (Keohane et
al., 1990).
Despite the variability in differential hypoxic cytotoxicity
for different cell lines shown for SR4233, values obtained
from different investigators are consistently higher than those
obtained for the quinone antibiotic mitomycin C, for which
values of only 1 to 5 are found (Fracasso & Sartorelli, 1986;
Keohane et al., 1990; Stratford & Stephens, 1989), and for
the 2-nitroimidazole misonidazole for which values of five to
15 are typical (Stratford & Stephens, 1989; Taylor & Rauth,
1978). However, comparable high values are often, though
not universally, reported for the dual function nitroimid-
azole, RSU 1069 (Adams et al., 1992; Roizin-Towle et al.,
1990; Stratford & Stephens, 1989).
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How much of a differential is necessary? One answer
would be that the differential should be large enough that
substantial killing of hypoxic cells occurs with little or no
killing of aerobic cells. This would be ideal, since it would
mean that the dose of an agent (such as radiation) that kills
well oxygenated normal cells would not have to be modified
when the bioreductive drug was given. For such a criterion a
factor of 10 or more would probably be adequate. Another
answer is that the differential should be as large as possible
because it is the cytotoxicity to aerobic cells which is likely to
produce systemic toxicity, and this needs to be kept to a
minimum. Thus, a drug design criterion would be that the
hypoxic cytotoxicity ratio should be at least 10 and pref-
erably larger. To date, of the bioreductive drugs in or nearing
clinical testing, only the benzotriazine di-N-oxide, SR4233,
and the bifunctional nitroimidazole, RSU 1069 (or its pro-
drug, RB 6145 (Jenkins et al., 1990)), fit this criterion.
Oxygen requirementfor preferential cytotoxicity
The profile of drug toxicity as a function of oxygen concen-
tration is an important, but often overlooked, characteristic
of bioreductive cytotoxic agents. Just how low an oxygen
level is needed to produce substantial differential hypoxic
cytotoxicity will determine how big a subpopulation in a
tumour is killed by the agent. Too low an oxygen level and
few cells in the tumour will be differentially susceptible. Too
high an oxygen level and various normal tissue cells will be
killed by the drug. Mitomycin C is an example of a drug for
which the hypoxia level is too stringent for maximum
efficacy, since extremely low levels of oxygen (of less than
0.01% or 100 parts per million) are required to obtain max-
imum sensitivity (Marshall & Rauth, 1986). This is con-
siderably lower than the oxygen level needed for maximum
sensitivity for misonidazole (Koch, 1990; Mulcahy, 1984) and
leaves cells at intermediate oxygen concentrations resistant to
both mitomycin C and to radiation (Marshall & Rauth,
1986).
Figure 2 shows calculated profiles of cell killing by X-rays,
SR 4233 and RSU 1069 as a function of oxygen concentra-
tion (Koch, personal communication, October 1992). These
calculations are based on a comprehensive study of the sur-
vival of V79 cells exposed to SR 4233, to RSU 1069 and to
misonidazole as a function of oxygen concentration (Koch,
1993). Although the aerobic/hypoxic ratios (HCR's) of
SR 4233 and RSU 1069 in this study were similar when cells
equilibrated with air were compared with those under ex-
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Figure 1 Survival of three cell lines to various concentrations of
SR 4233 for a 90 min exposure at 37°C under aerobic or hypoxic
conditions. The cell lines and their tumours of origin were:
SCCVII, a mouse squamous cell carcinoma; HT1080, a human
fibrosarcoma; and A549, a human lung carcinoma. The results
show the pooled data from 3-6 independent experiments for
each cell line with the lines drawn by eye. The dashed lines on the
panels for the two human tumour cell lines are a reproduction of
the curves from the SCCVII cells. Shown on the lower panel is
the method of calculating the hypoxic cytotoxicity ratio (HCR).
The method of achieving hypoxia was a modification of that
described by Koch which allowed rapid gas equilibration of the
cells attached to glass petri dishes (Koch, 1984). The average
oxygen concentration in the medium was measured using a Clark
type electrode (Koch, 1991) and was between 100 and 200 p.p.m.
during the 90 min exposure.
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Figure 2 Calculations of the cell killing by a fixed dose of
X-rays, SR 4233, RSU 1069 and the combination of X-rays with
each drug as a function of oxygen concentration (Koch, personal
communication, 1992). These calculation are based on
measurements of the cytotoxicity of various bioreductive drugs
(including RSU 1069 and SR4233) to V79 cells in vitro as a
function of oxygen concentration (Koch, 1993). The surviving
fractions for the drug + radiation groups are the product of the
independent survivals for drug (RSU 1069 or SR 4233) alone and
for X-rays alone and therefore assume no interaction between the
two agents. The dose ofeach agent has been chosen to produce a
maximum level of cell killing of approximately 102 when given
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treme hypoxia, the profile at intermediate oxygen concentra-
tions was quite different for the two drugs. Essentially,
SR 4233 maintains its 'hypoxic cytotoxicity' at oxygen con-
centrations approximately 10-fold higher than those of
RSU 1069. This results in the calculated additive killing pro-
duced by X-rays and SR 4233 being more uniform over the
whole range of oxygen concentrations than for X-rays with
RSU 1069. This is likely to be an advantage in tumours
which often have oxygen concentrations spanning the range
from extreme hypoxia to fully aerobic (Hockel et al., 1991;
Vaupel et al., 1991).
Mechanism ofhypoxic toxicity ofSR 4233
Several groups have investigated the mechanism for the selec-
tive hypoxic toxicity of SR 4233, and there is general agree-
ment on the broad outlines of the mechanism. Figure 3
shows a diagram of the proposed mechanism for the selective
cytotoxicity. It shows that the damaging species is an oxidis-
ing radical which is 'back-oxidised' to the parent drug in the
presence of oxygen. This oxidising radical abstracts hydrogen
from cellular targets leaving an oxidised target molecule
along with the stable 2-electron reduction product, SR 4317.
The principle evidence for the above mechanism is listed
below:
* When SR 4233 is added to mammalian cells under
hypoxic, but not aerobic, conditions, cytotoxicity occurs
as well as production of the metabolite, SR 4317. SR
4317, however, is toxic neither to hypoxic, nor aerobic,
cells, despite the fact that it is taken up by the cells
(Baker et al., 1988; Costa et al., 1989).
* The necessity for drug reduction to cause cytotoxicity is
supported by the quantitative relationship between reduc-
tion rates and cytotoxicity for different cell lines and
environmental conditions (Biedermann et al., 1991; Costa
et al., 1989).
* The hypothesis that a free radical is responsible for
cytotoxicity is supported by the finding that DMSO, a
potent radical scavenger, substantially reduces hypoxic
cytotoxicity (Brown, 1991).
* Definitive identification of the free radical has been
obtained using electron spin resonance, with the unpaired
electron being identified as primarily centred on the 1-
nitrogen (Lloyd et al., 1991). Evidence suggests that the
radical anion is protonated to form a neutral oxidising
radical capable of abstracting hydrogen from cellular
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targets (Baker et al., 1988; Laderoute et al., 1988). Also
supporting this is the finding that the Vmax and Km for
production ofthe radical (Lloyd et al., 1991) are the same
as the Vma, and Km for production of the 2-electron
reduction product, SR4317 (Walton & Workman, 1990).
* Under aerobic conditions, the superoxide radical has been
identified (Lloyd et al., 1991) as expected for an oxygen
dependent futile cycling reaction as shown in Figure 3.
Although there is agreement that the first reductive step to
the radical anion requires cellular enzymes, there is disagree-
ment as to the principal enzyme involved. Using mouse liver
microsomes as the enzyme source, Walton and co-workers
(Walton et al., 1992; Walton & Workman, 1990) identified
cytochrome P450 as the major reductase in SR4233 meta-.
bolism based on their finding of an approximately 80%
inhibition of metabolism by the P450 inhibitor, carbon
monoxide. Similarly, Wang and colleagues (Wang et al.,
1993) also identified cytochrome P450 as the major reductase
using homogenates of a mouse and a human tumour cell line.
On the other hand, Cahill and White and Lloyd and co-
workers (Cahill & White, 1990; Lloyd et al., 1991) found no
inhibition of reduction of SR4233 by rat liver microsomes
using carbon monoxide and identified NADPH cytochrome
P450 reductase as the major enzyme involved in drug reduc-
tion. Whether this disagreement reflects a difference between
mouse and human on the one hand and rat on the other, or
a technical problem with the carbon monoxide inhibition
experiments, is not clear at present.
What is the targetfor cell killing?
Various authors have shown that SR 4233 under hypoxic
conditions produces both single- and double-stranded breaks
in DNA (Laderoute et al., 1988; Zeman & Brown, 1989).
Data implicating DNA double-strand breaks as an important
lesion in SR 4233 hypoxic cytotoxicity were obtained by
Biedermann and colleagues (Biedermann et al., 1991), who
showed that two hamster cell lines, XRI and V3, which are
deficient in double-strand break rejoining and sensitive to
X-irradiation, are also more sensitive to killing by SR 4233
than expected from their rates of metabolism of the drug
under hypoxia.
More recently, definitive evidence that chromosome breaks
can entirely account for cell killing by SR 4233 under
hypoxia has been obtained for both hamster and human cells
(Wang et al., 1992, and unpublished). These investigators
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Figure 3 Schematic representation of the mechanism of cell killing by SR 4233 under hypoxic conditions. Cellular enzyme(s)
(reductase[s]) reduce the drug (by adding a single electron), thereby producing a free radical which, after protonation, abstracts H
from cellular molecules. In the case of DNA, this leads to single and double-strand breaks and to chromosome aberrations (which
cause cell killing). In the presence of oxygen, the SR 4233 radical is oxidised back to the parent molecule (with the concomitant
formation of 02--), thereby largely preventing the radical induced damage.1166 J.M. BROWN
performed a quantitative comparison of the initial and the
final number of chromosome breaks (using premature chro-
mosome condensation) from equitoxic doses of X-irradiation
and SR 4233 treatment. They showed that for equal cell
killing, the same number of chromosome breaks were found
for the two treatments after repair was complete. Since it is
well known that chromosome breaks can entirely account for
cell killing by ionising radiation (Cornforth & Bedford, 1987;
Revell, 1983), it would appear that the same is true for
SR 4233 exposure under hypoxia. Interestingly, however,
these investigators found fewer initial chromosome breaks
from SR4233 treated cells than from X-irradiated cells at
equal toxicity and showed that these breaks were less
repairable than the X-ray produced breaks. A model to
account for this finding is shown in Figure 4. It suggests that
the breaks produced by SR 4233 are produced by high local
concentrations of the activated radical as a consequence of
the close proximity of an activating reductase. Such high
local concentrations of radicals could produce highly damag-
ed DNA similar to that produced by densely ionising radia-
tion. Breaks such as these are less repairable than those
produced by sparsely ionising radiation such as X-rays (Bed-
ford & Goodhead, 1989; Prise et al., 1987).
An implication of this work showing the importance of
chromosome breaks, particularly if the model shown in
Figure 4 is correct, is that identification of enzymatic reduc-
tion from whole cells or from microsomes may not identify
the enzyme responsible for cytotoxicity, since this may reflect
only a fraction of the total cellular metabolism. Relevant to
this is the finding of Cahill and White that preparations of
rat liver nuclei were able to metabolise SR4233 to SR4317,
but at only 4% of the rate for rat liver microsomes (Cahill &
White, 1990). Yet, this minor component of the reduction
rate could be largely responsible for cytotoxicity.
To date, there are no published studies identifying either
the mechansim of cell killing or the cellular target for cyto-
toxicity of SR 4233 under aerobic conditions. Such killing
could be the result either of the parent SR 4233, the superox-
ide radical or the same SR 4233 radical as is responsible for
hypoxic cytotoxicity. The cellular target responsible for cell
killing by SR 4233 under aerobic conditions has not been
identified. Studies of both of these are important because the
systemic toxicity of the drug (assuming this is related to
aerobic toxicity) may be the result of a different mechanism
from that killing hypoxic tumour cells. If this were the case,
it is possible that the tumour cell toxicity could be increased
without changing the systemic toxicity or the systemic tox-
icity could be decreased without changing tumour cell tox-
icity, thereby increasing the therapeutic ratio.
Does SR 4233 preferentially kill hypoxic cells in tumours?
The fact that SR 4233 preferentially kills hypoxic cells in vitro
is no guarantee that it also preferentially kills hypoxic cells in
solid tumours because of such problems as inadequate diffus-
ion, too rapid metabolism or prohibitive systemic toxicity.
Mitomycin C, for example, while demonstrating modest pre-
ferential killing of hypoxic cells in vitro, shows little or no
preferential killing of hypoxic cells in mouse tumours (Rock-
well & Kennedy, 1979). Zeman and colleagues investigated
this question by combining SR 4233 with a single dose of
irradiation given to mouse tumours (Zeman et al., 1988).
They found a roughly 20-fold increase of cell kill over that
expected from the toxicity of radiation alone and that of
SR 4233 alone. Although this is consistent with preferential
killing of hypoxic cells, they also found that there was an
interaction between the cytotoxicities of irradiation and
SR 4233 under hypoxia which complicated the interpretation.
More definitive experiments have recently shown that the
'radiobiological' hypoxic fraction in SCCVII tumours (deter-
mined by the paired survival curve method) falls to approx-
imately 8% of pretreatment levels by 1 h following SR 4233
injection (Kim & Brown, 1993). These and other experiments
with fractionated irradiation (see below) strongly suggest that
SR 4233 is preferentially cytotoxic to hypoxic cells in rodent
solid tumours.
How should SR 4233 be used clinically?
To date, there are no clinical studies with a drug which is
specifically toxic to hypoxic cells. It might be argued that the
clinical trial of mitomycin C plus radiotherapy (Weissberg et
al., 1989) is an example of such a study. However, mitomycin
C is toxic, not only to hypoxic, but also to aerobic cells, and
there is often little or no differential toxicity between hypoxic
and aerobic cells (Fracasso & Sartorelli, 1986; Stratford &
Stephens, 1989). Also, the drug was given only once during
the course of the 6-week radiotherapy regimen, which, on
theoretical grounds, would not be expected to modify the
response compared to radiation alone if only hypoxic cells
were killed (Brown & Koong, 1991). Thus, although the
positive result of the combination compared to radiotherapy
Figure 4 A model to account for the 'high LET' like damage caused in DNA by SR 4233 under hypoxia. The presence of an
activating enzyme close to DNA would be expected to produce a high local concentration of activated SR 4233 radicals (shown
emerging from the active site of the enzyme), each of which can produce a single strand break in the DNA. Also shown are
representations of the ionisation densities in the tracks of a low and high LET ionising particles.SR 4233: A NEW BIOREDUCTIVE ANTICANCER DRUG 1167
alone is encouraging, it is unlikely that this was the result of
preferential killing of radiobiologically resistant hypoxic cells.
Two ways in which a bioreductive drug such as SR4233
could be given clinically have been identified from preclinical
studies. These are outlined below:
(a) In combination with an agent which increases tumour
hypoxia It has been known for a number of years that
certain vasoactive drugs can produce selective tumour
hypoxia (Cater et al., 1962; Voorhees & Babbs, 1982). Such
hypoxia is a result of decreased tumour blood flow which, if
prolonged, can produce cell killing in its own right. This
appears to be the major mechanism for the antitumour
action of flavone acetic acid (Zwi et al., 1989). It might be
predicted, then, that enhanced tumour cytotoxicity would be
produced by combining one of these agents with a bioreduc-
tive cytotoxic agent. Results supporting this hypothesis have
in fact been obtained for a combination of the vasodilating
drug, hydralazine, with RSU 1069 (Chaplin & Acker, 1987;
Bremner et al., 1990), or with SR 4233 (Brown, 1987).
SR4233 has also been shown to enhance the antitumour
effect of flavone acetic acid in murine tumours (Sun &
Brown, 1989).
Thus, it would appear from these preclinical data that
SR 4233, or other bioreductive cytotoxic drugs, could be
effectively used with any agent that selectively increases
hypoxia in human tumours. Unfortunately, it is yet to be
demonstrated that decreased tumour blood flow and/or in-
creased hypoxia can be produced in human tumours. None-
theless, this remains a viable strategy for the use of a
bioreductive drug.
(b) In combination with fractionated irradiation A theore-
tical study by Brown and Koong has suggested that hypoxia
in tumours can be an advantage to radiation therapy if an
agent specifically toxic to hypoxic cells can be given with
most of the radiation doses (Brown & Koong, 1991). They
demonstrated that a hypoxic cell cytotoxin could produce
more tumour cell killing (by several orders of magnitude)
than that produced by full oxygenation of the tumour or by
use of an optimum hypoxic cell radiosensitiser, provided the
cytotoxin kills more than -50% of the hypoxic cells each
time it is given. Experimental verification of this concept has
come from studies combining SR 4233 with fractionated
irradiation of mouse tumours (Brown & Lemmon, 1990).
Essentially, the authors found, using both growth delay and
cell survival, that it was more effective to combine SR 4233,
rather than a massive dose of the radiation sensitiser,
SR 2508, with each radiation dose in a multifraction regimen.
Figure 5 shows data from this study demonstrating that
SR 4233 produces an apparently greater than additive res-
ponse when combined with fractionated irradiation. How-
ever, the calculated 'additive' response is misleading in that it
assumes a homogenous cell population in the tumour. If it is
assumed that the tumour has aerobic cells preferentially
killed by ionising radiation and hypoxic cells preferentially
killed by SR 4233, then a response essentially identical to
that observed experimentally is predicted (Brown & Lem-
mon, 1990).
This enhancement of the antitumour effect with fractionat-
ed irradiation has been shown to be specific for the tumour,
as there was no enhancement of early skin reactions (Brown
& Lemmon, 1991b) or late reactions (Brown & Lemmon,
1991a) produced when SR 4233 was combined with frac-
tionated irradiation.
Is there potential to combine SR 4233 with chemotherpy?
Although the data from clinical studies on the role of tumour
hypoxia are not as compelling for chemotherapeutic agents
as they are for ionising radiation, there is nonetheless
evidence from preclinical studies that the hypoxic cells in
solid tumours are refractory to certain chemotherapy drugs
either because of their intrinsic hypoxia, their distance from
blood vessels, their low repair capacity or their slower rate of
proliferation (Kennedy, 1987; Sartorelli, 1988; Tannock &
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Figure 5 Response of SCCVII tumours to SR 4233 alone
(0.1 lmmol/kg/injection), to X-rays alone (2.5 Gy/fraction every
12 h) and a combination of the two (SR 4233 given 30 min before
each radiation dose). The mice were sacrificed and the tumours
removed to obtain clonogenic cell survival 12 h after the last
dose. The lines are best fit least squares regression lines cons-
trained to pass through I at zero dose. The line marked
'Additive' shows the product of the survivals for X-rays and for
SR 4233 alone. Pooled data from two experiments. Redrawn
from Brown and Lemmon (1990) with permission of the pub-
lisher.
Guttman, 1981). If this is the case, then an improvement in
the therapeutic index might be expected by combining the
chemotherapeutic agent with a drug selectivity toxic to
hypoxic cells. This was the initial rationale for the combina-
tion of the nitroimidazole hypoxic cytotoxic agents with
various anticancer drugs, and results with one drug, doxo-
rubicin, demonstrated that this rationale appeared to hold
(Tannock, 1980).
This success encouraged several investigators to study
nitroimidazole/anticancer drug interactions, and it soon
became obvious that the nitroimidazoles could produce a
therapeutic gain when combined with various anticancer
agents, particularly the alkylating agents cyclophosphamide
and melphalan, and the nitrosoureas BCNU and CCNU
(Siemann, 1984). However, it became clear that the thera-
peutic gain produced by these agents was not the conse-
quence of selective killing of hypoxic cells, but of other
mechanisms including a potentiation of DNA crosslink for-
mation by breakdown products of the nitroimidazoles
(Taylor et al., 1983).
With the advent of more potent bioreductive drugs than
the nitroimidazoles (e.g., SR 4233 and RB 6145), there is now
an opportunity for the first time to test in a rigorous manner
the hypothesis that selective targeting of the hypoxic cells in
solid tumours can enhance the effectiveness of certain anti-
cancer drugs. Early studies with SR4233 by Holden and
colleagues (Holden et al., 1992) are encouraging in this
regard. These investigators found that they were able to
markedly potentiate the tumour cell killing of cisplatin, mel-
phalan, cyclophosphamide and BCNU when the tumour-
bearing mice were given a large single dose of SR 4233 at the
same time as the anticancer drug. Although the authors also
observed some potentiation of bone marrow toxicity, they
found a therapeutic gain for each of these antitumour agents.
Recent studies by Dorie and Brown (unpublished) have also
demonstrated that SR 4233 produces a large, schedule-depen-
dent enhancement of tumour cell kill by cisplatin. These data
encourage further studies, particularly as they raise a number
of important questions. For example, it is not clear that the
potentiation of tumour cell killing by the anticancer drugs is
the result of a selective killing of chemotherapy resistant
hypoxic cells. Studies to investigate the mechanism and
clinical potential of this approach are clearly required.
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Can SR 4233 be given in sufficiently high doses with daily
radiotherapy?
As mentioned previously, theoretical studies of the combina-
tion of radiation with a hypoxic cytotoxic agent suggests that
for optimum enhancement of tumour cell kill, the drug is
best given with each radiation dose (Brown & Koong, 1991).
Toxicological studies have been performed giving the drug
daily (5 x per week) for 6 weeks to mice at doses which
produce substantial enhancement of fractionated irradiation
(Spiegel et al., 1993). These authors found that such a dose
was well-tolerated by the mice, producing no weight loss and
no observable histopathological toxicity, but reduced peri-
pheral white cell count to a steady level of approximately
30% of normal during the 6 weeks of injections. This white
cell depression, plus a 20% drop in hematocrit, led the
authors to suggest that the dose-limiting toxicity for daily
injections of SR 4233 would be myelosuppression.
In assessing whether tumour cell cytotoxic doses can be
given daily to man, it is necessary to know whether the
cytotoxicity to hypoxic cells depends on area under the curve
(AUC) ofdrug concentration x time. This has been establish-
ed for hamster cells exposed in vitro for periods of from
20 min to 4 h (Tosto & Brown, unpublished). Assuming that
this is the case in vivo, then toxicological studies already
performed in dogs show that AUC values sufficient to pro-
duce hypoxic cell cytotoxicity can be achieved with nontoxic
daily doses of SR 4233 (Hincks et al., personal communica-
tion). Thus, knowledge of maximum tolerated doses and the
pharmacokinetics of SR 4233 from currently ongoing Phase 1
studies will determine whether efficacious doses will be possi-
ble on a daily dose basis in man. Assuming values close to
these are achievable, then this will provide substantial
encouragement to further work with SR 4233 or its analogs.
Unanswered questions
Major unanswered questions for the biological activity of
SR4233 and analogs are listed below:
(a) The enzyme(s) responsible for metabolism of SR 4233
close to DNA Apart from the obvious interest of determin-
ing these enzymes, the practical use of an assay for such
nuclear localised enzymes would be to determine whether the
in vivo efficacy for individual human solid tumours could be
predicted. The greater the activity of such enzyme in an
individual tumour, the more sensitive one would expect the
tumour to be to killing by SR4233 under hypoxia.
(b) The mechanism, and critical cellular target, for the tox-
icity of SR 4233 to cells under aerobic conditions From
Figure 1, showing the mechanism for hypoxic cytotoxicity, it
is apparent that the aerobic toxicity could be the result of the
parent compound, the superoxide anion radical or the drug
radical. No convincing evidence exists to decide among these
three possibilities. Also unknown is the cellular target
damage to which is primarily responsible for killing of cells
under aerobic conditions. An important application of such
knowledge would be that if systemic toxicity was related to
aerobic toxicity and if aerobic and hypoxic toxicity had
different mechanisms or target molecules, then it might be
possible to increase tumour cell kill without changing
systemic toxicity or decrease systemic toxicity without chang-
ing hypoxic toxicity.
(c) Mechanism for bone marrow toxicity in vivo It is not
clear why bone marrow cells are more susceptible to the
aerobic toxicity of SR 4233, and, if so, which blood precursor
cell is most sensitive. Again, this may help to alleviate the
systemic toxicity of the drug.
Closing remarks
Preclinical studies and theoretical modeling have demon-
strated that the combination of SR4233 with fractionated
irradiation of a solid tumour can produce several orders of
magnitude more cell kill than that produced by radiation
alone. It appears that this strategy is superior to the use of
hypoxic cell radiosensitisers or agents which can oxygenate
the hypoxic cells. Such an effect depends on the solid tumour
containing hypoxic cells which are regenerated during ther-
apy, a process analogous to reoxygenation during fraction-
ated radiotherapy which we have termed 'rehypoxiation'. We
know, at least, that a sizeable fraction (perhaps 40 to 50%)
of human tumours contain hypoxic cells, but not whether the
phenomenon of rehypoxiation occurs in human tumours.
However, if human tumours behave in a similar manner to
rodent tumours in this regard and if the human is not
especially sensitive to the systemic toxicity of SR 4233 com-
pared to mice and dogs, then substantial extra cell killing of
the cells of solid tumours should be obtainable with SR 4233
combined with fractionated radiotherapy. The extent of this
extra cell killing should lead to substantial increases in local
control rates. These considerations qualify SR 4233 as the
lead compound in an interesting new series of bioreductive
drugs of clinical potential.
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